5:52 PM
 | 
Oct 24, 2006
 |  BC Extra  |  Top Story

Lonza to buy Cambrex units

CBM will sell its research bioproducts and microbial biopharma businesses to Lonza (SWX:LONN) for $460 million in cash. LONN said the bioproducts business will provide it with raw materials and testing services and allow it to sell...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >